These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

535 related items for PubMed ID: 24814862

  • 1. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
    Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, Suzuki T, Aoki T, Watanabe T, Maruyama D, Yokoyama M, Takubo T, Kagehara H, Matsushima T.
    Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
    [Abstract] [Full Text] [Related]

  • 2. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J.
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [Abstract] [Full Text] [Related]

  • 3. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, Pillon M, Aladjidi N, Klingebiel T, Landman-Parker J, Medina-Sanson A, August K, Sachs J, Hoffman K, Kinley J, Song S, Song G, Zhang S, Suri A, Gore L.
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [Abstract] [Full Text] [Related]

  • 4. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F.
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
    Koga Y, Sekimizu M, Iguchi A, Kada A, Saito AM, Asada R, Mori T, Horibe K.
    Int J Hematol; 2020 May; 111(5):711-718. PubMed ID: 31960285
    [Abstract] [Full Text] [Related]

  • 6. Brentuximab vedotin for the treatment of CD30+ lymphomas.
    Foyil KV, Bartlett NL.
    Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
    [Abstract] [Full Text] [Related]

  • 7. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM.
    Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
    [Abstract] [Full Text] [Related]

  • 8. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M, Iguchi A, Mori T, Koga Y, Kada A, Saito AM, Horibe K.
    BMC Cancer; 2018 Feb 01; 18(1):122. PubMed ID: 29390984
    [Abstract] [Full Text] [Related]

  • 9. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A.
    N Engl J Med; 2010 Nov 04; 363(19):1812-21. PubMed ID: 21047225
    [Abstract] [Full Text] [Related]

  • 10. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS.
    Ann Pharmacother; 2012 Mar 04; 46(3):377-83. PubMed ID: 22395252
    [Abstract] [Full Text] [Related]

  • 11. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
    Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM.
    Lancet Oncol; 2018 Sep 04; 19(9):1229-1238. PubMed ID: 30122620
    [Abstract] [Full Text] [Related]

  • 12. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
    Izutsu K, Ogura M, Tobinai K, Hatake K, Sakamoto S, Nishimura M, Hoshino M.
    Int J Hematol; 2021 Mar 04; 113(3):404-412. PubMed ID: 33392974
    [Abstract] [Full Text] [Related]

  • 13. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R.
    J Clin Oncol; 2012 Jun 20; 30(18):2183-9. PubMed ID: 22454421
    [Abstract] [Full Text] [Related]

  • 14. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
    Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A.
    J Hematol Oncol; 2014 Mar 19; 7():24. PubMed ID: 24642247
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.
    Hirai Y, Sakurai J, Yoshida S, Kikuchi T, Mitsuhashi T, Miyake T, Fujimura T, Abe R, Fujikawa H, Boki H, Suga H, Shibata S, Miyagaki T, Shimauchi T, Kiyohara E, Kawakami Y, Morizane S.
    J Dermatol; 2024 Aug 19; 51(8):1037-1049. PubMed ID: 38874430
    [Abstract] [Full Text] [Related]

  • 16. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
    Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder NN, Engert A.
    Cancer Chemother Pharmacol; 2013 Jul 19; 72(1):241-9. PubMed ID: 23719719
    [Abstract] [Full Text] [Related]

  • 17. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
    Garnock-Jones KP.
    Drugs; 2013 Mar 19; 73(4):371-81. PubMed ID: 23494187
    [Abstract] [Full Text] [Related]

  • 18. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A.
    J Clin Oncol; 2012 Jun 20; 30(18):2190-6. PubMed ID: 22614995
    [Abstract] [Full Text] [Related]

  • 19. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
    Chen R, Chen B.
    Drug Des Devel Ther; 2015 Jun 20; 9():1729-33. PubMed ID: 25848209
    [Abstract] [Full Text] [Related]

  • 20. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
    Bradley AM, Devine M, DeRemer D.
    Am J Health Syst Pharm; 2013 Apr 01; 70(7):589-97. PubMed ID: 23515511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.